CORDIS
EU research results

CORDIS

English EN

New Medicines for Trypanosomatidic Infections

Objective

The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people’s lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drugs, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and Brazil). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners’expertise and the integrated platform that will provide:
- at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones,
- early phase biomarkers for efficacy prediction (overall improved efficacy and safety)
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

Address

Via Universita 4
41121 Modena

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 889 824,31

Administrative Contact

Maria Paola Costi (Prof.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

European ScreeningPort GmbH

Germany

EU Contribution

€ 87 281,18

BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN

Germany

EU Contribution

€ 502 965

INSTITUTO DE BIOLOGIA MOLECULAR E CELULAR-IBMC

Portugal

EU Contribution

€ 469 318,80

UNIVERSITA DEGLI STUDI DI SIENA

Italy

EU Contribution

€ 340 740

HITS GGMBH

Germany

EU Contribution

€ 581 808,80

TYDOCK PHARMA S.r.l

Italy

EU Contribution

€ 388 570

NATIONAL CENTER FOR RESEARCH

Sudan

EU Contribution

€ 158 860

Hypha Discovery Limited

United Kingdom

EU Contribution

€ 392 793,85

ETHNIKO IDRYMA EREVNON

Greece

EU Contribution

€ 447 492,19

UNIVERSIDAD COMPLUTENSE DE MADRID

Spain

EU Contribution

€ 445 484,80

Interface Europe

Belgium

EU Contribution

€ 254 339,02

CENTRO NACIONAL DE PESQUISA EM ENERGIA E MATERIAS ASSOCIACAO PRIVADA

Brazil

EU Contribution

€ 325 965,20

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.

Germany

EU Contribution

€ 615 968

Project information

Grant agreement ID: 603240

Status

Closed project

  • Start date

    1 February 2014

  • End date

    31 January 2017

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 639 176,11

  • EU contribution

    € 5 901 411,15

Coordinated by:

UNIVERSITA DEGLI STUDI DI MODENA E REGGIO EMILIA

Italy